DM Intelligence Picked up ￥10M in Angel Round of Financing

(VCBeat) Apr. 25, 2021 -- On April 19, 2021, Guangzhou-based DM Intelligence, a new drug R&D company, announced that it had secured nearly ten million yuan in the angel funding round, led by Guangzhou Nanshan Venture Capital. Financial terms of the transaction were not disclosed. The funds are earmarked for the construction of DM Intelligence's core platform (the AI-powered new drug discovery platform) and the pre-clinical development of its AI-driven new drugs.

Based on a large number of diversified databases, with a variety of optimized machine learning and deep learning algorithms combined with intelligent CADD as the core, aiming at new drug HIT, LEAD discovery, PCC optimization as the goal, and supercomputer as the accelerator, DM Intelligence has established an AI-based platform for drug discovery based on drug activity and ADMET property prediction, drug-target interaction and small molecule generation, with advantages in the speed, precision and breadth of innovative drug discovery.

Dr. Xie Weidong, the chairman and general manager of DM Intelligence, said, "Combined with AI technology, the company has started the fast forward mode of AI-based new drug R&D, established a comprehensive algorithm model from multiple dimensions, and greatly improved the screening efficiency. DM Intelligence has discovered novel and diversified active compounds with global patents. Currently, the company focuses on the pipeline of proven and urgently needed small-molecule drugs for targeted therapies of cancer, neurodegeneration, infection and autoimmunity. The company's AI-based drug discovery platform shows amazing potential.

"After more than two years of development, DM Intelligence has developed more than 10 internal pipelines, 5 pipelines with external cooperation. The pipeline for Parkinson's disease is progressing rapidly and has shown excellent results compared with similar drugs in development. Next, DM Intelligence will focus on the relevant pipelines to further promote the development of the enterprise. The AI platform of DM Intelligence integrates multiple disciplines such as pharmaceutical chemistry, biology, mathematics, and bioinformatics to establish a comprehensive algorithm model from multiple dimensions. The screening efficiency is much higher than traditional methods, and many compounds developed by the platform have been granted global patent protection," said Xie Weidong.

Guangzhou Nanshan Venture Capital is a fund for scientific and technological achievement transformation, led by Zhong Nanshan, academician of Chinese Academy of Engineering, under the management of Guangdong Nanshan Medical Innovation Research Institute. The fund mainly invests in research institutions in biomedical and related fields, new R&D companies, and transformation projects of scientific and technological achievements in universities and colleges.